

CyGenics Ltd • Australia • Level 4 • 414 Lonsdale Street • Melbourne 3000
Phone 61 (0)3 9642 5580 • Facsimile 61 (0)3 9462 5581
Singapore • 600 North Bridge Road • #12-09/10 Parkview Square • Singapore 188778
Phone (65) 6238 0808 • Facsimile (65) 6295 1108 • www.cygenics.com



For Immediate Release

CyGenics strengthens Melbourne operations

16th MAY 2005 – CyGenics Ltd. (ASX: CYN), a leading adult stem cell biotechnology and immunotherapy company, today announced the appointment of a new team to strengthen its Melbourne-based operations in preparation for the commencement of clinical trials.

Medical Director, Dr Anne Altmann, will lead the team. Dr Altmann has a first class honours degree in medicine from Monash University and is a fellow of the Royal Australasian Public Health Physicians. She has been involved in medicine and medical research since 1992, including senior appointments at the Royal Children's Hospital Research Institute and at Monash University. Prior to joining the CyGenics group, Dr Altmann was Head of Department, at the International Centre for Therapeutic Research, Servier Laboratories (Australia) Pty Ltd where she managed the implementation and successful completion of over 20 international Phase II and III clinical trials.

Assisting as Medical Consultant will be Dr Katie Allen. Dr Allen performed Australia's first clinical liver cell transplant in 2004. She has been a Fellow of the Royal Australian College of Physicians since 1998 and received her PhD in cell therapy in 2002. She is the Principal Research Fellow of the Liver Cell/Stem Cell Research Group at the Murdoch Children's Research Institute and is a Paediatric Gastroenterologist at the Royal Children's Hospital.

Dr Sahar Bassal will assist as Research and Clinical Trials Coordinator. Dr Bassal joined the company in April 2004 and has been instrumental in guiding the transfer of the company's technology from Boston to Melbourne and preparing the groundwork for the clinical trials program. Dr Bassal completed her PhD in 1996 and was awarded a post-doctoral position under the Fogarty Fellowship Program of the NIH, USA. In addition, Dr Bassal has held senior post doctoral positions with Peter MacCallum Cancer Institute and the Baker Medical Research Institute. Sahar also gained considerable international experience through her time at the Bioinformatics and Advanced Biotechnology group at Johnson and Johnson Pharmaceuticals in Belgium.

Ms Cynthia Elliot, Director of Quality Assurance & Regulatory Affairs, will guide the team through various regulatory and quality issues and requirements from her base in NJ, USA. Ms Elliot has worked in various US hospitals and research institutions. She has also served on a number of committees for the American Association of Blood Banks and the International Society for Cellular Therapy.

"We are very excited to have such an experienced team in place. This is an important step in our clinical trial program," said Steven Fang, Chief Executive Officer of CyGenics.

About CyGenics



CyGenics is a biotechnology and immunotherapy company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates three divisions: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

Ronald Hee Corporate Communications & Marketing Manager CyGenics Ph: +61 3 9642 5580 Email: ronald.hee@cygenics.com	Rebecca Piercy Buchan Consulting Ph: +61 3 9866 4722 Mob: 0422 916 422 Email: rpiercy@bcg.com.au
---	--